CervoMed Inc. (CRVO) Stock Price & How to Invest

Last updated November 2026

Short answer

You can invest in CervoMed (CRVO) by buying shares or fractional shares at any major broker, through an ETF that holds it, or as one holding in a thematic basket. CervoMed is a clinical-stage biotech whose value rests almost entirely on neflamapimod, an oral drug it is developing for dementia with Lewy bodies (DLB). The thesis is that neflamapimod's anti-inflammatory mechanism can slow this hard-to-treat neurodegenerative disease, but the company has no approved product, no product revenue, and a flagged going-concern risk. As of October 16, 2026 the stock closed at $2.26, down about 71% in 2026, for a market value near $34 million. This is a highly speculative micro-cap with binary trial outcomes, so a disappointing readout or a financing crunch could erase much of the value.

CRVO stock price

As of 2026-11-16, CervoMed Inc. (CRVO) last closed at $1.67, down 79.7% over the past year. Over the past 52 weeks it has traded between $1.37 and $9.94.

CRVO last close
$1.67
1 day
-1.18%
1 month
-25.45%
1 year
-79.66%
52-week range
$1.37 to $9.94
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or CervoMed Inc.'s investor relations page. Walnut is informational, not investment advice.

CRVO key stats

At $1.67 on November 16, 2026, CervoMed Inc. (CRVO) has a market cap of $25M.

Market cap
$25M
Price to book
1.5

Market cap, P/E and yield are measured at the $1.67 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with CervoMed Inc. (CRVO)?

The last two weeks for CervoMed Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • CRVO closed at $1.67 on November 16, 2026, up 16.8% over the past five trading days (from $1.43).
  • On November 16, 2026, CervoMed Inc. filed an 8-K with the SEC reporting information shared with investors (Regulation FD) and other events (Item 7.01, Item 8.01). Read the 8-K on sec.gov
  • On November 9, 2026, CervoMed Inc. filed an 8-K with the SEC reporting quarterly results (Item 2.02). Read the 8-K on sec.gov
  • On November 6, 2026, CervoMed Inc. filed its quarterly report (10-Q) with the SEC. Read the 10-Q on sec.gov

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

What does CervoMed Inc. (CRVO) do?

CervoMed is a clinical-stage biopharmaceutical company developing neflamapimod, an oral small-molecule inhibitor of p38 MAP kinase alpha, which the company says targets the neuroinflammation and synaptic dysfunction that drive neurodegenerative disease. Its lead program is in dementia with Lewy bodies (DLB), a common and serious form of dementia with few approved treatments. CervoMed is also exploring neflamapimod in additional indications such as frontotemporal disorders, nonfluent variant primary progressive aphasia, and recovery-related neurology programs, but DLB is the central driver of the story.

The company became public through a 2023 reverse merger with Diffusion Pharmaceuticals and trades on Nasdaq as CRVO. Its defining moment came in December 2024, when the Phase 2b RewinD-LB trial missed its primary endpoint (change in CDR sum-of-boxes) and key secondary endpoints; management attributed the result largely to low plasma drug concentrations tied to a drug-substance issue during the double-blind phase, and the stock fell sharply. Through 2025 CervoMed reported positive extension-phase and within-subject results plus supportive biomarker data (including reductions in plasma GFAP), and in November 2025 it aligned with the FDA on a potential registration path in DLB. The second half of 2026 brought a run of development news. In August, neflamapimod received an Innovation Passport under the UK's Innovative Licensing and Access Pathway for DLB. On September 28, CervoMed reported that a new 50 mg tablet using the most stable crystalline form of the drug matched the exposure of the old capsule with steadier levels, and that the FDA had removed the plasma exposure limit on dosing after a 39-week dog toxicology study; future trials are planned at 100 mg twice daily. On October 12, initial open-label results from a 25-patient Phase 2a trial in nonfluent variant primary progressive aphasia showed a decline in plasma neurofilament light chain over 12 weeks, with 24-week data due at CTAD in November 2026 and topline clinical data in Q1 2027. Financially, the company reported about $24.9 million of cash and no debt at June 30, 2026, after a roughly $10.5 million June private placement that was expected to extend the runway into the second quarter of 2027, and a Q2 2026 net loss of about $6.6 million. It still discloses substantial doubt about its ability to continue as a going concern and is seeking a strategic partner to fund a Phase 3 DLB study. None of the news has lifted the stock: it closed at $2.26 on October 16, 2026, down about 71% year to date and 70% over one year.

What's driving CervoMed Inc. (CRVO)?

1. Differentiated mechanism in a high-unmet-need disease.

Neflamapimod is an oral inhibitor of p38 MAP kinase alpha that CervoMed positions as targeting the neuroinflammation and synaptic dysfunction underlying dementia with Lewy bodies. DLB is one of the most common dementias and has very few approved disease-specific therapies. A drug that meaningfully slows progression would address a large unmet need. The mechanism and oral dosing differentiate it from many other neuro programs.

2. Supportive secondary and biomarker data.

Although the RewinD-LB primary endpoint missed in December 2024, CervoMed reported positive extension-phase and within-subject results during 2025, along with biomarker changes such as reductions in plasma GFAP and shifts in amyloid ratios. Management argues these signals, plus a drug-supply explanation for the topline miss, support advancing to Phase 3. Investigators presented results at scientific conferences including AD/PD and CTAD. These data are the basis of the remaining bull case.

3. Phase 3 plan and partnering strategy.

CervoMed has outlined a single global, randomized, placebo-controlled Phase 3 trial in roughly 300 DLB patients, after aligning with the FDA on a potential registration path in November 2025. It has not set a start date: the stated priority is to secure a strategic partner to finance and advance the program, and the company acknowledges that a partnership may not happen. The September 2026 tablet results and the FDA's removal of the exposure limit address the drug-supply problem blamed for the Phase 2b miss, and the UK Innovation Passport adds a regulatory route outside the US. A partnership or licensing deal would be a major validating event and could reduce dilution risk. It is also pursuing patent protection covering DLB use into 2042.

4. Pipeline optionality beyond DLB.

Beyond the lead DLB program, CervoMed has explored neflamapimod in frontotemporal disorders, nonfluent variant primary progressive aphasia, and other neurology settings. In October 2026 it presented initial Phase 2a results in nfvPPA showing a reduction in plasma neurofilament light chain, a marker of nerve damage, over 12 weeks in 25 patients, with 24-week biomarker data due in November 2026 and topline clinical data in Q1 2027. The study is small and open-label, and regulators may not accept the biomarker as a predictor of benefit. These are extra shots on goal from a single molecule, secondary to the DLB outcome.

What are the risks to CervoMed Inc. (CRVO)?

CervoMed is an extremely speculative micro-cap with no approved products and no product revenue, so its fate hinges on a single asset, neflamapimod, in a disease where its key Phase 2b already missed its primary endpoint. Outcomes are binary: a failed or delayed Phase 3, a regulatory setback, or an inability to secure a partner could sharply reduce or wipe out the value, and the Phase 3 start now depends explicitly on finding that partner. Management has flagged substantial doubt about the company's ability to continue as a going concern, and with about $24.9 million of cash at June 30, 2026 against a trailing net loss of about $30 million, further capital raises are likely and could heavily dilute existing shareholders; the share count has already risen to roughly 15 million. The nfvPPA data so far is open-label biomarker data without a control group. Single-asset concentration, ongoing losses, and reliance on external financing make the stock high-risk and capable of total loss, as its roughly 71% decline in 2026 shows.

What is the CervoMed Inc. (CRVO) forecast?

5 analysts publish price targets on CRVO, averaging $14.80 as of November 2026, or +786.2% against the $1.67 share price on November 16, 2026. The published targets run from $6.00 to $25.00, a wide spread, and the ratings split 6 buy, 0 hold, 0 sell. Over the last six months there have been 0 raises and 1 cut among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full CRVO forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is CRVO a buy or a sell?

We give no verdict on CervoMed Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Differentiated mechanism in a high-unmet-need disease. Neflamapimod is an oral inhibitor of p38 MAP kinase alpha that CervoMed positions as targeting the neuroinflammation and synaptic dysfunction underlying dementia with Lewy bodies. The most optimistic published target, $25.00, assumes this works close to its best case.

The case against. CervoMed is an extremely speculative micro-cap with no approved products and no product revenue, so its fate hinges on a single asset, neflamapimod, in a disease where its key Phase 2b already missed its primary endpoint. The most pessimistic target, $6.00, is roughly what CRVO is worth if this bites instead.

Read the full bull and bear case on CRVO, including what would have to change to break either one. Walnut is not an investment adviser.

Has CervoMed Inc. (CRVO) split its stock?

Yes. CervoMed Inc. (CRVO) has had 3 share splits in the last 10 years:

  • 1:15 on December 14, 2018, so every share held became 0.06666666666666667 shares.
  • 1:50 on April 19, 2022, so every share held became 0.02 shares.
  • 2:3 on August 17, 2023, so every share held became 0.6666666666666666 shares.

A split changes the share count and the price per share and leaves the value of a holding unchanged. Someone holding $1,000 of CRVO the day before the 2:3 split held $1,000 the day after, in more shares at a proportionally lower price. Historical prices from before the date are normally shown split-adjusted, which is why a long-run chart shows no cliff.

Splits matter mainly because they make older price figures confusing to compare by hand, and because a board choosing to split is usually signalling that the price has run up far enough to feel awkward for smaller buyers. Neither is a reason to buy or sell.

How is CervoMed Inc. (CRVO) valued?

Market cap, P/E and dividend yield at today's price are in the CRVO key stats above. The business figures below come from CervoMed Inc.'s reported results as of October 2026 and change when it next reports.

  • Product revenue: None (clinical-stage; grant revenue lapsed to $0 in 2026)
  • Net loss (Q2 2026 / TTM): ~$6.6 million / ~$30.4 million
  • Cash & equivalents (Jun 30, 2026): ~$24.9 million, no debt
  • Cash runway: Expected into Q2 2027 after ~$10.5M June 2026 placement; going-concern doubt disclosed
  • Shares outstanding: ~15 million (implied by market cap)

As of October 2026: A single-asset clinical biotech like CervoMed cannot be valued on earnings, revenue, or P/E because it has none; its market value reflects a probability-weighted guess at neflamapimod's commercial potential, discounted heavily for trial and financing risk. At about $34 million the market cap is only modestly above the roughly $25 million of cash, so investors are assigning little value to the drug itself, even as five covering analysts carry a mean target near $15. Partnering news, the November 2026 CTAD data, and financing terms are the variables that can swing the implied value most.

Who competes with CervoMed Inc. (CRVO)?

Lewy body / dementia neuro biotechs

Other companies pursuing dementia with Lewy bodies, Parkinson's-related dementia, and broader neurodegeneration compete for patients, investigators, and investor attention. Examples include developers such as Cognition Therapeutics and other small CNS-focused biotechs working on Lewy body or Alzheimer's-adjacent programs.

Large CNS / neuroscience players

Established neuroscience companies such as Biogen, Eisai, AbbVie, and Eli Lilly have far greater resources, approved or late-stage neuro assets, and the scale to run large dementia trials, setting a high competitive and commercial bar for a micro-cap.

Biotech ETFs and alternatives

Investors wanting biotech exposure without single-stock risk often use broad funds like the SPDR S&P Biotech ETF (XBI) or iShares Biotechnology ETF (IBB). Tiny clinical-stage micro-caps like CRVO are rarely meaningful holdings in major ETFs, so index exposure to it is usually negligible.

What stocks are similar to CervoMed Inc. (CRVO)?

Other names that sit close to CRVO: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in CervoMed Inc. (CRVO)

There are three common ways to get CRVO exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so CRVO sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where CRVO fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on CervoMed Inc. (CRVO)

CervoMed is a single-asset, pre-revenue biotech whose stock tracks the perceived odds of neflamapimod succeeding in dementia with Lewy bodies and of the company finding a partner to fund Phase 3. It behaves like a binary clinical-biotech bet: it can move sharply on trial data, financing news, and partnership headlines, and after a roughly 70% fall over the past year it carries a real risk of large or total loss.

More on CervoMed Inc. (CRVO)

Whether CRVO is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is CRVO a buy or a sell?, and where the stock could go from here in the CRVO stock forecast.

For income investors, whether CRVO pays a dividend and how the payout looks is covered in does CRVO pay a dividend? And to weigh CRVO against a peer, read the full side-by-side comparisons: CRVO vs CNS and CRVO vs BIIB.

Wondering how CRVO fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about CervoMed Inc.

Ask Walnut's AI anything about CRVO and see how it fits what you own.

FAQ

What does CervoMed do?

+

CervoMed is a clinical-stage biopharmaceutical company developing neflamapimod, an oral drug aimed at the neuroinflammation behind neurodegenerative disease. Its lead program is in dementia with Lewy bodies (DLB), with additional early-stage work in other neurology indications. It has no approved products and no product revenue, and funds itself by raising capital while it runs clinical trials.

What is neflamapimod?

+

Neflamapimod is CervoMed's lead drug candidate, an oral small-molecule inhibitor of p38 MAP kinase alpha. The company says it targets the neuroinflammation and synaptic dysfunction that drive diseases like dementia with Lewy bodies. It is the core of CervoMed's value, having been studied in the Phase 2b RewinD-LB trial and slated for a planned Phase 3 study in DLB.

What happened with the RewinD-LB readout?

+

In December 2024, the Phase 2b RewinD-LB trial missed its primary endpoint (change in CDR sum-of-boxes) and key secondary endpoints, and the stock fell sharply. Management attributed the miss largely to low plasma drug concentrations tied to a drug-substance issue. During 2025 the company reported positive extension-phase and biomarker data it argues support moving to Phase 3, and in September 2026 it reported that a new, more stable tablet formulation fixes the supply problem and that the FDA removed its drug exposure limit.

Does CRVO pay a dividend?

+

No. CervoMed does not pay a dividend. It is a pre-revenue, clinical-stage biotech that reinvests all available capital into drug development and preserves cash to fund trials, so any potential return to shareholders would come only from share-price changes, not income.

Why is CRVO stock so volatile?

+

CervoMed's value depends almost entirely on one drug, neflamapimod, so the stock swings sharply on trial data, financing announcements, partnership news, and conference presentations. Single-asset, pre-revenue micro-cap biotechs are inherently volatile because each event can dramatically change the company's prospects, and a going-concern flag adds financing-driven risk. Over the past 52 weeks CRVO has traded between about $2.13 and $10.00.

Which ETFs or baskets include CRVO?

+

As a tiny clinical-stage micro-cap, CervoMed is rarely a meaningful holding in major ETFs; broad biotech funds like XBI or IBB may include it only in negligible amounts, if at all. In Walnut you could hold CRVO as one constituent of a thematic basket, for example a speculative neuroscience or small-cap biotech theme, sized to the risk you are willing to take.

Is CRVO a good stock?

+

This is descriptive, not advice. Bulls point to neflamapimod's mechanism, supportive 2025 extension and biomarker data, FDA alignment on a registration path, the removal of the FDA exposure limit, early nfvPPA biomarker data, and patent protection into 2042. Bears emphasize that this is a highly speculative single-asset micro-cap that already missed its Phase 2b primary endpoint, has no revenue, carries a going-concern warning, has no Phase 3 partner yet, and may dilute shareholders heavily. Whether it fits depends on your own goals and risk tolerance.

Is CRVO a good stock to buy right now?

+

This is informational, not a recommendation. CervoMed is a pre-revenue, clinical-stage biotech with binary outcomes: the value largely hinges on finding a partner for neflamapimod's Phase 3, the nfvPPA readouts due in November 2026 and Q1 2027, and the company's limited cash runway, and the downside risk includes substantial loss. Walnut provides information, not investment advice, so any decision should reflect your own research, time horizon, and tolerance for high risk.

What did CervoMed report in its latest quarter?

+

For Q2 2026 CervoMed reported no revenue and a net loss of about $6.6 million, or $0.64 per share, narrower than the $0.86 loss analysts expected. It ended June 2026 with about $24.9 million of cash and no debt after a June private placement. The next report is expected around November 12, 2026.

How has CRVO stock performed in 2026?

+

CRVO closed at $2.26 on October 16, 2026, down about 71% year to date and about 70% over the past twelve months, near the bottom of a 52-week range of roughly $2.13 to $10.00. It fell about 22% over the last three months despite the tablet, FDA and nfvPPA news. Walnut is not an investment adviser; these figures are descriptive.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with CervoMed Inc.'s investor relations page or your broker before making investment decisions.